A clinical stage biopharmaceutical company that discovers and develops novel allosteric ion channel modulators for treating central nervous system disorders, with lead candidates including BNC210 for social anxiety disorder and post-traumatic stress disorder, and other programs targeting cognitive dysfunction, cancer, and neuropsychiatric conditions.